Celwise AB Uses ExOne 3D Printed Tooling to Transform Wood Fiber into Innovative, Single-Use Plastic Replacement
7.9.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, is proud to announce that innovative molded fiber technology supplier, Celwise AB of Norrköping, Sweden, is using metal tools 3D printed by ExOne in 316L stainless steel for its patented method of transforming wood and other cellulose fibers into a wide range of eco-friendly packaging and products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005199/en/
Celwise's innovative and sustainable molded fiber products, which replace single-use plastics, are shown in front of the X1 160Pro™ production metal 3D printer. A key part of Celwise’s patented production method for producing this all-new type of molded fiber product is uniquely featured metal tooling that can only be made with additive manufacturing, such as ExOne’s binder jetting technology. (Photo: Business Wire)
Invented, developed and patented over the past 10 years, Celwise technology aims to transform the paper and plastics industry with its innovation, which produces a water-resistant molded fiber product that looks and feels like a luxurious blend of wood and plastic. Celwise technology is enjoying rapid success, with adoption projects now underway with a wide range of global companies serving many industries, including consumer products, food and beverage, cosmetics, and electronics.
“Our planet needs this technology now,” said David Pierce, Inventor and Co-Owner of Celwise. “Our patented technology delivers a recyclable, renewable, and biodegradable product that can be manufactured faster and more affordably than traditional technologies. Advanced manufacturing approaches, which rely on 3D printed tooling from ExOne, are an important part of our process.”
“Celwise is demonstrating how new technologies such as binder jet 3D printing can help solve some of the world’s toughest problems,” said John Hartner, ExOne’s CEO. “We’re proud to collaborate with Celwise on delivering this important innovation.”
How it Works
Celwise’s patented process includes unique tooling and machines, as well as a novel process, to deliver its final product. Common cellulose fiber-based (paper) product manufacturing slowly removes water from cellulose fiber for molded products that must be coated for water resistance.
Celwise, however, rapidly removes water in a new process that enables cellulose fibers to re-bond with each other quickly, creating a new type of paper product that is strong, wood-like, and water-resistant.
What’s more, because a series of forming, transferring and pressing tools are 3D printed using ExOne binder jetting technology, the process gives Celwise even more design freedom to develop their client’s products.
ExOne’s binder jet 3D printing transforms powdered materials — metal, sand or ceramic — into highly dense and functional precision parts at high speeds. An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time, similar to printing on sheets of paper.
When printing metals, such as the Celwise tools, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
ExOne is now providing prototype and production tools to Celwise specifications. While other metal 3D printing processes can produce the types of tools required by Celwise, Pierce estimates that ExOne binder jetting technology delivers a 20% time savings over those processes as well as a cost savings of 30-40%.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005199/en/
Contact information
Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
